Commentary

Article

SRNA’s Educational Micro-Course: Building a Greater Understanding of Rare Neuroimmune Disorders

Author(s):

Benjamin Greenberg, MD, a pediatric neurologist at the University of Texas Southwestern Medical Center, provided commentary on a recently initiated online program dedicated to empowering those affected by rare neuroimmune disorders.

Benjamin Greenberg, MD

Benjamin Greenberg, MD

Rare neuroimmune disorders are complex autoimmune disorders of the central nervous system that occur when the immune system mistakenly attacks tissue. These disorders can have lifelong complications and affect several aspects of a person’s life. The Siegel Rare Neuroimmune Association (SRNA), an advocacy group with 30 years in the field, has been at the forefront of raising awareness and improving the lives of those with such conditions, which include acute disseminated encephalomyelitis (ADEM), acute flaccid myelitis (AFM), MOG antibody disease (MOGAD), neuromyelitis optica spectrum disorder (NMSOD), optic neuritis (ON), and transverse myelitis (TM).

About a month ago, the organization released several new courses as part of its unique online learning program, which provides patients and families living with these disorders a comprehensive understanding of their condition. Each course, which features videos with helpful animations, written text, and knowledge checks, was developed with medical experts and aims to improve knowledge and health literacy, reduce diagnostic uncertainty, and provide resources for better patient-care discussions.

Benjamin Greenberg, MD, vice chair of Clinical & Translational Research at the University of Texas Southwestern Medical Center, provided an overview of the course and the educational opportunities it provides patients and families. Greenberg, a professor and the Cain Denius Scholar in Mobility Disorders in the Department of Neurology, also commented on the style of the program, the growing awareness of these disorders, and the steps patients should take if they are unsure about their diagnosis.

What are some of the greatest advantages this course holds for patients and families affected by rare neuroimmune disorders?

Benjamin Greenberg, MD: This course is well organized, created from a patient/family’s perspective, and uses accessible language and concepts to describe complex medical topics. The content is separated into sections that allow for the digestion of the material over time.

How does the style of the courses allow for easier digestion of material and a greater understanding of these disorders?

The material utilizes accessible visualizations and comparisons to make complex material understandable. The integration of the visualizations with narration provides a powerful tool for families navigating medical issues for the first time.

What are the key aspects of education that are pertinent to patients gaining control over their disease?

In the world of rare neuroimmunologic disorders, there is a tremendous complexity to the various diagnostic categories. Often patients and families hear conflicting information about their diagnosis and this educational program provides a thorough and understandable education about how to understand the terminology and concepts. Additionally, the program provides families with important information about treatment options and approaches to monitoring for disease activity.

Over the years, how has awareness of the differences between these disorders grown? What are things the public and clinicians should still keep in mind when thinking about rare neuroimmune disorders?

Over the years there has been a growth in awareness about rare neuroimmunologic disorders partly driven by scientific advances that separated out diagnostic approaches to neuromyelitis optica and anti-MOG associated disorder. With an evolving landscape of diagnoses and nomenclature clinicians and patients need a framework to keep track of the diagnostic and management issues.

For patients who are still confused about their diagnosis, what steps should they take?

If after this program patients are still confused about their diagnosis it is often because they have incomplete information. It will be critical to discuss these questions with their treating care providers.

Related Videos
Adam Numis, MD; Laura Kirkpatrick, MD
Jessica Nickrand, PhD; Allyson Eyermann
Jacqueline A. French, MD
Julie Ziobro, MD, PhD; John Schreiber, MD
Adam Numis, MD; Laura Kirkpatrick, MD
Jessica Nickrand, PhD; Allyson Eyermann
Jacqueline A. French, MD
Alexander C. Whiting, MD
© 2024 MJH Life Sciences

All rights reserved.